Taysha Gene Therapies secures $40 million term loans via Trinity

By Marisa Wong

Los Angeles, Dec. 19 – Taysha Gene Therapies, Inc. signed a loan and security agreement on Nov. 13 with Trinity Capital Inc. as administrative agent for $40 million of term loans, according to a Tuesday press release.

With the term loan, Taysha believes it will be able to fund its operating expenses and capital requirements into 2026 to support the clinical development of its TSHA-102 program in Rett syndrome.

Based in Dallas, Taysha is a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.